EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Predictive Biomarkers in Metastatic Colorectal Cancer Patients Treated With Bevacizumab: A Turkish Oncology Group ( TOG ) Study

Büsra Akay Hacan, Fatma Gizem Sonugür, Müge Öçal, Cansu Babahan, Samira Abgarmi, Ülkü Yalçıntaş Arslan, Mehmet Ali Şendur, Ahmet Demirkazık, Güngör Utkan, Hakan Akbulut iD

International Journal of Cancer · 15.10.2026 · 159 (8) · 2075-2083

DOI: 10.1002/ijc.70588 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 11.06.2026. Verfasst von Büsra Akay Hacan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara, Turkey. Hauptthemen laut MEDLINE: Bevacizumab, Colorectal Neoplasms, Biomarkers, Tumor, Antineoplastic Agents, Immunological. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Türk Onkoloji Grubu Derneği, Türkiye Bilimsel ve Teknolojik Araştırma Kurumu.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Efforts to improve outcomes for patients with metastatic colorectal cancer (mCRC) treated with bevacizumab are limited by the lack of validated predictive biomarkers. To overcome this challenge, our study prospectively assessed the combined prognostic and predictive significance of circulating angiogenic biomarkers and T‐cell subsets. Eighty‐eight patients with unresectable mCRC were prospectively enrolled. Pre‐treatment serum levels of VEGF, bFGF, PDGF‐B, and endothelin‐1 (ET‐1) were measured by ELISA, nitric oxide by colorimetric assay, and T‐cell subsets by flow cytometry. Bevacizumab trough levels and anti‐bevacizumab antibodies were assessed by ELISA. Higher baseline levels of proangiogenic factors, including VEGF, PDGF‐B, and ET‐1, were associated with improved survival. Based on these findings, we developed a novel Angiogenesis Index (AI) using the cut‐off values for VEGF, PDGF‐B, and ET‐1. This AI was a significant predictor of efficacy for bevacizumab‐based therapy for both PFS and OS. Furthermore, bevacizumab trough levels exceeding 25 μg/mL on day 14 were associated with improved OS. Likewise, patients with lower baseline circulating FoxP3+ regulatory T cells (Treg) tended to have improved survival. The AI, bevacizumab trough levels, and baseline Treg levels are promising biomarkers for predicting efficacy and refining patient selection for bevacizumab therapy in mCRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabColorectal NeoplasmsBiomarkers, TumorAntineoplastic Agents, ImmunologicalHumansFemaleMaleMiddle AgedAgedPrognosisEndothelin-1Prospective StudiesAdultVascular Endothelial Growth Factor ATurkeyNeoplasm MetastasisAngiogenesis InhibitorsAged, 80 and overNeovascularization, Pathologic

Stichwörter der Autor:innen

PDGF‐BVEGFbevacizumabcolorectal cancerendothelin‐1

Substanzen

BevacizumabBiomarkers, TumorEndothelin-1Vascular Endothelial Growth Factor AAntineoplastic Agents, ImmunologicalAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara, Turkey.
  • Center for BioNanoengineering, Houston Methodist Research Institute, Houston, Texas, USA.
  • Department of Basic Oncology, Ankara University Cancer Research Institute, Ankara, Turkey.
  • Department of Medical Biology, Yuksek İhtisas University Faculty of Medicine, Ankara, Turkey.
  • Department of Medical Oncology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.
  • Department of Medical Oncology, University of Ankara Yıldırım Beyazıt, Ankara Bilkent City Hospital, Ankara, Turkey.

ORCID-Profile: Hakan Akbulut

Förderung

  • Türk Onkoloji Grubu Derneği
  • Türkiye Bilimsel ve Teknolojik Araştırma Kurumu

Zitieren

APA

Hacan, B. A., Sonugür, F. G., Öçal, M., Babahan, C., Abgarmi, S., Arslan, Ü. Y., Şendur, M. A., Demirkazık, A., Utkan, G., & Akbulut, H. (2026). Predictive Biomarkers in Metastatic Colorectal Cancer Patients Treated With Bevacizumab: A Turkish Oncology Group ( TOG ) Study. International Journal of Cancer, 159(8), 2075-2083. https://doi.org/10.1002/ijc.70588

Vancouver

Hacan BA, Sonugür FG, Öçal M, Babahan C, Abgarmi S, Arslan ÜY, et al. Predictive Biomarkers in Metastatic Colorectal Cancer Patients Treated With Bevacizumab: A Turkish Oncology Group ( TOG ) Study. International Journal of Cancer. 2026;159(8):2075-2083. doi:10.1002/ijc.70588

BibTeX
@article{Hacan2026,
  author = {Hacan, Büsra Akay and Sonugür, Fatma Gizem and Öçal, Müge and Babahan, Cansu and Abgarmi, Samira and Arslan, Ülkü Yalçıntaş and Şendur, Mehmet Ali and Demirkazık, Ahmet and Utkan, Güngör and Akbulut, Hakan},
  title = {Predictive Biomarkers in Metastatic Colorectal Cancer Patients Treated With Bevacizumab: A Turkish Oncology Group ( TOG ) Study},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {159},
  number = {8},
  pages = {2075--2083},
  doi = {10.1002/ijc.70588}
}
Kostenlos starten →